Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
This Phase 2 study was to determine the incidence of increased serum aminotransferase
concentrations (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST]), as
well as the overall safety and tolerability of ambrisentan, in participants with pulmonary
arterial hypertension (PAH), idiopathic PAH (IPAH), or familial PAH (FPAH) who had previously
discontinued ERA therapy (bosentan or sitaxsentan) due to increased serum ALT or AST
concentrations.